Home » FDA Approves Aeterna Zentaris’ IND Application for Doxorubicin
FDA Approves Aeterna Zentaris’ IND Application for Doxorubicin
Aeterna Zentaris announced that the FDA has approved the company’s Investigational New Drug (IND) application for its doxorubicin targeted conjugate compound, AEZS-108, in luteinizing hormone releasing hormone or LHRH receptor positive urothelial or bladder cancer.
RTTNews
RTTNews
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May